Fig. 6

Metformin inhibits the growth of H446 and H526 cells in vivo. (A,E) Images of isolated tumours from each group after treatment with saline, metformin, cisplatin, or metformin + cisplatin (n = 5). (B,F) Growth of the subcutaneous tumours in each group. The tumour volume was calculated on the basis of measurements with a calliper every 3 days. (C,G) The tumour weight in each group was measured after isolation from the female mice. (D,H) The body weights of the female mice after treatment with saline, metformin, cisplatin, or metformin combined with cisplatin for 21 days. Statistical analyses were performed via ANOVA, which revealed significant differences compared with the untreated control: *p < 0.05; **p < 0.01; ***p < 0.001. n = 5. (I) Images of HE staining and IHC staining (Ki-67 and p-AMPK) of tumour tissues from subcutaneous xenograft models (magnification: ×200). (J) Schematic description of the main molecular mechanism by which metformin suppresses SCLC growth.